- Home
- AGCC vs OVID Comparison
AGCC vs OVID Comparison
Compare AGCC & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGCC | OVID |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | Taiwan | United States |
| Employees | 23 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.8M | 365.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AGCC | OVID |
|---|---|---|
| Price | $18.65 | $2.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 95.7K | ★ 2.5M |
| Earning Date | 05-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | $168.97 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $4.23 | $0.27 |
| 52 Week High | $25.73 | $3.11 |
Technical Indicators
Market Signals| Indicator | AGCC | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 56.16 |
| Support Level | $13.30 | $2.56 |
| Resistance Level | $25.35 | $3.11 |
| Average True Range (ATR) | 3.08 | 0.16 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 43.23 | 51.72 |
Price Performance
Historical ComparisonAbout AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares
Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.